SSNC Filings — SS&C Technologies Holdings, Inc. - FilingSpy
SSNC
SS&C Technologies Holdings, Inc.
SS&C Technologies builds software and runs the back-office machinery of finance and healthcare, from trading systems and retirement accounts to pharmacy claims processing, serving tens of thousands of clients including hedge funds and health plans. It began in 1986, when Bill Stone launched the firm as Security Software & Consulting Inc. from the basement of his Connecticut home. A fun twist: it gobbled up Blue Prism, the British firm whose founders actually coined the term "robotic process automation."
Q2 FY2026 revenue rose 10.3% to $1,695.7M on $117.6M of organic growth
accelerated to $117.6M this quarter, the largest in two years. rose 10.3% to $1,695.7M, rose 34.7% to $0.97, and widened to 48.3% as grew only 2.2%. The business is growing faster on its own, but $7.3B of sits against it.
Key takeaways
rose 10.3% to $1,695.7M, driven by $117.6M in from , Wealth and Investment Technology, and , with technology-enabled services revenue up 11.1% to $1,408.2M.
rose 34.7% to $0.97 and rose 29.9% to $234.8M, while rose 21.1% to $417.1M as increased only 2.2% to $401.2M from lower personnel costs.
widened to 48.3% from 48.0% a year earlier as total cost of revenues rose 9.7% to $877.4M, slower than growth.
Section summaries
Management's Discussion and Analysis
Q2 FY2026 revenue rose 10.3% to $1.7B on organic growth in fund admin and wealth tech; operating margin expanded as expenses grew slower than revenue.
⌄
Total revenues increased 10.3% to $1,695.7M, driven by $117.6M in from , Wealth and Investment Technology, and .
was $416.7M in the quarter, up 11.7% and up 39.0% from Q1, while rose 15.3% to $403.4M.
The stood at 1.70x against a 6.25x , with $363.4M available under the ; $4.86B of remains rate-exposed.
What changed
Q2 FY2026 was $117.6M versus the $50.9M Q2 FY2025 figure and $75.9M Q1 FY2026 figure, confirming the pace accelerated without acquisition reliance (acquisitions added $35.9M to tech-enabled services this quarter).
License, maintenance and related was not separately reported this quarter after dipping to $239.8M in Q1 FY2026, leaving the organic license decline unresolved against the prior flag.
Health Business unit assessment remains a continuing from the FY2025 10-K with no update given in this filing.
Net was not stated this quarter; the prior flag noted $4.7B rate exposure, and this filing updates variable-rate debt to $4.86B with a 100 rise adding ~$48.6M annual interest expense, partially offset by ~$12.8M from client cash.
Risk factors were restated with no material changes from the FY2025 10-K, so no new company-specific risk emerged this quarter.
What to watch
Q3 FY2026 against the $117.6M Q2 figure to see if the acceleration holds with in the base.
Next quarter's net under the Incremental Term B-8 Loan as $4.86B remains rate-exposed with a 100-bp move worth $48.6M.
FY2026 Health Business unit assessment given its continuing status.
Q3 FY2026 license, maintenance and related to see if the quarterly organic license declines reverse after the Q1 dip to $239.8M.
Technology-enabled services grew 11.1% to $1,408.2M, with of $101.6M and $35.9M from acquisitions.
Total cost of revenues rose 9.7% to $877.4M, slower than growth, lifting to 48.3% from 48.0% a year ago.
Operating expenses increased only 2.2% to $401.2M as organic expenses fell $7.9M, mainly from lower personnel costs, while acquisitions added $15.5M.
Net was $716.4M for the six months; financing outflows of $736.1M included $605.7M in share repurchases and $129.3M in dividends.
The stood at 1.70x as of June 30, 2026, with $363.4M available under the .
The information regarding certain legal proceedings in which we are involved as set forth in Note 13 – Commitments and Contingencies of the Notes to the Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report on Form 10-Q) is incorporated by referenc…
⌄
The information regarding certain legal proceedings in which we are involved as set forth in Note 13 – Commitments and Contingencies of the Notes to the Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report on Form 10-Q) is incorporated by reference into this Item 1.
In addition, we are involved in various other legal proceedings arising in the normal course of our businesses. At this time, we do not believe any material losses under these claims to be probable. While the ultimate outcome of such legal proceedings cannot be predicted with certainty, it is in the opinion of management, after consultation with legal counsel, that the final outcome in such proceedings, in the aggregate, would not have a material adverse effect on our consolidated financial condition, results of operations or cash flows.
As of the date of this report, there have been no material changes to the risk factors we previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025. 25
⌄
As of the date of this report, there have been no material changes to the risk factors we previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.
25